Division of Gastroenterology and Hepatology, Stanford University, Alway Building, Room M211, 300 Pasteur Drive, Stanford, CA 94305, USA.
Division of Gastroenterology and Hepatology, Stanford University, Alway Building, Room M211, 300 Pasteur Drive, Stanford, CA 94305, USA.
Clin Liver Dis. 2018 Aug;22(3):563-578. doi: 10.1016/j.cld.2018.03.007.
Primary biliary cholangitis (PBC) is a chronic disease that progresses to end-stage liver disease. Ursodeoxycholic acid (UDCA), the standard treatment for PBC for several decades, is associated with improved survival without liver transplantation. Approximately 40% of patients do not respond to UDCA. Because of disease variability, several prognostic models exist that incorporate various factors including biochemical response to UDCA. Useful for patient care and counseling as well as risk stratification for research and clinical trials, the role of these models in the pre-UDCA and UDCA eras is discussed.
原发性胆汁性胆管炎（PBC）是一种慢性疾病，可进展为终末期肝病。熊去氧胆酸（UDCA）作为 PBC 数十年的标准治疗药物，可改善未经肝移植患者的生存率。大约 40%的患者对 UDCA 无应答。由于疾病的变异性，存在几种预后模型，这些模型纳入了包括对 UDCA 的生化应答在内的各种因素。这些模型在 UDCA 治疗前和 UDCA 治疗时代均有助于患者的治疗和咨询以及研究和临床试验的风险分层，其作用在此进行讨论。
